Compare Novartis AG (NVS) vs Zoom Video Communications, Inc. (ZM) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Zoom Communications (ZM) trades at $96.44, down 4.83% amid mixed signals. The stock shows bearish technical indicators with support at $95 and resistance at $99, while fundamentals reveal strong profitability with 77.3% gross margins and 65.19% net income margin. Recent Q2 earnings beat expectations with 4.9% revenue growth to $1.28B, but soft Q3 guidance triggered the selloff. Analyst consensus remains cautiously optimistic with a $119.63 price target despite near-term headwinds.

The outlook balances strong cash flow generation against growth deceleration concerns. Investment opportunity lies in ZM's enterprise revenue acceleration (7.8% growth) and attractive valuation (P/E 8.95), while risks include competitive pressure and execution on AI initiatives. The Anthropic IPO catalyst and new board appointment provide potential upside if growth reaccelerates.